PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years
- Conditions
- Encephalitis, Tick-borne
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 615
- Registration Number
- NCT00161889
- Locations
- 🇩🇪
Hauptstrasse 9, Bietigheim-Bissingen, Germany
🇩🇪Marktplatz 33, Bad Saulgau, Germany
🇩🇪Salzgasse 11, Calw, Germany
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
- Conditions
- Encephalitis, Tick-borne
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00161746
- Locations
- 🇦🇹
Brauhausgasse 1, Mürzzuschlag, Austria
🇦🇹Wiener Strasse 50/2, Kapfenberg, Austria
🇦🇹Fronleichnamsweg 10, Liezen, Austria
TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)
- Conditions
- Encephalitis, Tick-Borne
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 375
- Registration Number
- NCT00161967
- Locations
- 🇦🇹
Grieskirchner Strasse 17, Wels, Upper Austria, Austria
🇵🇱Niepubliczny ZOZ, Zamosc, Poland
🇩🇪Hauptstrasse 240, Kehl, Germany
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.
- Conditions
- Tick-borne Encephalitis
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00161772
- Locations
- 🇩🇪
Rastatter Strasse 7, Mannheim-Secken, Germany
🇩🇪Solothurner Strasse 2, Heilbronn, Germany
🇦🇹Grieskirchner Strasse 17, Wels, Austria
Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years
- Conditions
- Tick-borne Encephalitis
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 340
- Registration Number
- NCT00161785
- Locations
- 🇵🇱
Szpital Jana Pawla II Oddzial Neuroinfekcji, Krakow, Poland
🇵🇱Hospital in Debica - Zespo Opieki Zdrowotnej w Debicy, Debica, Poland
Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
- Conditions
- Tick-borne Encephalitis
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00161863
- Locations
- 🇵🇱
Szpital Jana Pawla II Odz. Neuroinfekcji, Krakow, Poland
🇩🇪Solothurner Strasse 2, Heilbronn, Germany
🇵🇱PANTAMED sp.z.o.o., Olsztyn, Poland
Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD
- Conditions
- Cardiovascular Diseases
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8600
- Registration Number
- NCT00159835
- Locations
Pfizer Investigational Site
Voriconazole For Chronic Bronchopulmonary Aspergillosis
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2010-01-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT00159822
- Locations
- 🇫🇷
Pfizer Investigational Site, Suresnes, France
Effect Of A Treatment Optimization Program To Improve Satisfaction With Viagra
- Conditions
- Impotence
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8000
- Registration Number
- NCT00159848
Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia
- Conditions
- Pain
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-03-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 315
- Registration Number
- NCT00159640
- Locations
Pfizer Investigational Site